12 Red Days In A Row: BridgeBio Pharma Stock Is Down 11%
A dozen days of losses for BridgeBio Pharma are drawing attention to a business with conflicting financial signals.
BridgeBio Pharma (BBIO) has seen its stock price fall for 12 consecutive trading days, a slide that has erased 11% from its shares. The sustained selling has cut about $1.8 billion from the company’s market value, which now stands at about $15 billion.
For anyone holding the stock, this consistent downward pressure marks a significant shift from its performance earlier in the year.
The Streak Next To The S&P 500
Here is how BBIO stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | -0.8% | -0.4% |
| 12D (Current Streak) | -10.9% | 0.1% |
| 1M (21D) | -9.6% | 0.1% |
| 3M (63D) | 10.7% | 4.5% |
| YTD 2026 | -2.2% | 12.8% |
| 2025 | 178.8% | 16.4% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
What do the fundamentals suggest about this slide?
The market appears to be weighing a complex financial picture. Its revenue over the last twelve months grew 202.4%, far exceeding the S&P 500 median of 8.4%. Yet that growth comes with an operating margin of -67.0%, in stark contrast to the S&P 500 median of 18.6%. The company also has negative trailing earnings.
This move is specific to the stock. Over the same 12 trading days, the S&P 500 returned +0.1%, indicating the pressure on BBIO is not from the broader market.
A streak is information, not an instruction.
A long run in one direction is a signal of sustained momentum and investor attention. The disciplined move is not to chase or flee the trend, but to check the business against the price. While the stock’s one-month return is -9.6%, its trailing three-month return is still +10.7%.
Over the trailing twelve months, the stock has returned +44.4%. A streak prompts an investor to re-evaluate if the current price is justified by the company’s underlying health and prospects, and these figures provide a starting point for that assessment.
If the drop has you weighing an entry, resist buying a falling price alone. Our Buy the Dip screen ranks the marked-down names where growth and cash generation still support a recovery.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.